TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29668354
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser treatment three times per week for 8 weeks, along with usual hormonal treatment
Study: 23126316
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser GaAlAs, energy density of 4 J/cm(2), power of 100 mW, wavelength in the infrared spectrum, for 10 seconds per point on 10 points, total dose of 40 J/cm(2)
Study: 21439849
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids plus α-tocopherol (920 mg EPA, 760 mg DHA, 8 mg α-tocopherol per day)
Study: 21439849
Drug: α-tocopherol supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-tocopherol supplement (100 mg/week resulting in 14.2 mg/day)
Study: 18310524
Drug: Dexamethasone or
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone or tadalafil (prophylactic treatment)
Study: 16503545
Drug: Selaginella (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selaginella (30 g) daily in 50 ml decoction during the entire course of radiotherapy
Study: 16503545
Drug: Selaginella (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selaginella (30 g) daily in the late course of radiotherapy
Study: 8345163
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride 20 mg/day
Study: 3886298
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg ibuprofen 4-times daily
Study: 3508329
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg naproxen twice daily
Study: 29061311
Drug: Amoxicillin 1000mg
Normalized name: AMOXICILLIN 1000MG/CLAV K 62.5MG SA TAB
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1000mg three times per day for 10 days
Study: 30248105
Drug: Nilvadipine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine (8 mg sustained-release, once daily after breakfast)
Study: 1316259
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (15,000 aXaU) administered 2 hours before surgery (Group A, 19 patients)
Study: 1316259
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (15,000 aXaU) administered 2 hours after surgery (Group B, 21 patients)
Study: 22958237
Drug: Low vision
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vision rehabilitation (LVR) with 2 or 3 therapy sessions (1½ to 2½ hours) and homework to teach effective use of remaining vision and LV devices.
Study: 22958237
Drug: Basic low
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic low vision (LV) with devices dispensed by the optometrist without LV therapy, contact time for dispensing is one hour or less.
Study: 20149619
Drug: LPro (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPro (0.50 g protein·kg body weight⁻¹·day⁻¹)
Study: 20149619
Drug: MPro (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPro (0.75 g protein·kg body weight⁻¹·day⁻¹)
Study: 20149619
Drug: HPro (1.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPro (1.00 g protein·kg body weight⁻¹·day⁻¹)
Study: 15917519
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg every 12 h, intravenously or orally)
Study: 15917519
Drug: Vancomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 g every 12 h, intravenously)
Study: 10327426
Drug: Psilocybin (PSI;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (PSI; 0.2 mg/kg)
Study: 10327426
Drug: 3,4‐methylenedioxyethylamphetamine (MDE;
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,4‐methylenedioxyethylamphetamine (MDE; 2 mg/kg)
Study: 10327426
Drug: d‐methamphetamine (METH;
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐methamphetamine (METH; 0.2‐0.4 mg/kg)
Study: 8619714
Drug: Autotransfusion (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autotransfusion (10 mL/kg of whole blood removed before cardiopulmonary bypass)
Study: 6744776
Drug: Sotalol, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol, 40 to 160 mg/day
Study: 17992396
Drug: Dexamethasone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.2 mg/kg, three times at intervals of 36 hours)
Study: 10865301
Drug: Limited home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited home rehabilitation program with weekly telephone support from a psychiatric nurse (n=53)
Study: 8232944
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg lamotrigine
Study: 8232944
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg lamotrigine
Study: 16004014
Drug: Botox injections
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox injections
Study: 16562686
Drug: Sevoflurane‐N2O inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane‐N2O inhalation anaesthesia with LMA
Study: 16562686
Drug: Propofol‐ketamine total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol‐ketamine total intravenous anaesthesia (TIVA)
Study: 12973819
Drug: 500-mg clarithromycin
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mg clarithromycin tablet
Study: 11121914
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 500 mg/daily plus placebo (UDCA group, n=44)
Study: 11121914
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 500 mg/daily plus colchicine 1 mg/daily (UDCA/C group, n=46)
Study: 11121914
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 500 mg/daily plus colchicine 1 mg/daily (UDCA/C group)
Study: 11121914
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 500 mg/daily plus placebo (UDCA group)
Study: 1610160
Drug: Untasted salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untasted salt tablets (120 mmol/day)
Study: 29939053
Drug: Family-Enhanced Nondirective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Enhanced Nondirective Supportive Therapy (FE-NST)
Study: 15321808
Drug: Met (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Met (30 mg methionine/kg body wt)
Study: 15321808
Drug: MetSer (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MetSer (30 mg methionine + 60.6 mg serine/kg body wt)
Study: 15321808
Drug: MetCys (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MetCys (30 mg methionine + 12.3 mg cystine/kg body wt)
Study: 15321808
Drug: Protein (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein (30 mg methionine + 60.6 mg serine + 12.3 mg cystine/kg body wt)
Study: 7709864
Drug: Distribution of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distribution of sugar-coated chloroquine tablet
Study: 3315176
Drug: Lorazepam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1.5 mg/m2)
Study: 17345064
Drug: Topiramate (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (75 mg/day for 9 days)
Study: 10319784
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine (10 micrograms/kg in 7 ml saline followed by 6 micrograms/kg/h for 12 hours)
Study: 10319784
Drug: Bupivacaine (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.5% 7 ml followed by 0.25% 7 ml/h for 12 hours)
Study: 10319784
Drug: Bupivacaine (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.25% 7 ml followed by 0.125% 7 ml/h for 12 hours)
Study: 1841829
Drug: Oral immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunoglobulin preparation (monomeric IgG, 90% concentration), 500 mg per day, subdivided into 5 doses for 65 neonates
Study: 28210859
Drug: Peloid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peloid therapy + splint treatment (every night for 6 weeks + five consecutive days a week for 2 weeks)
Study: 28210859
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (splint treatment alone, every night for 6 weeks)
Study: 24592984
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) plus Cimicifugae racemosae (CR)
Study: 19124693
Drug: Delta9-Tetrahydrocannabinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta9-Tetrahydrocannabinol (10 mg)
Study: 16025317
Drug: zolpidem (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: zolpidem (10 mg)
Study: 8469621
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg 3 times/day
Study: 8469621
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg 3 times/day
Study: 8469621
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg 3 times/day
Study: 3219992
Drug: Drug information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug information sheets issued
Study: 3219992
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug information sheets issued
Study: 18617122
Drug: Propofol, 1
Normalized name: Propofol, 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol, 1 mg/kg
Study: 18617122
Drug: Landiolol, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol, 0.1 mg/kg
Study: 18617122
Drug: Nicardipine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine, 1 mg
Study: 10834523
Drug: Ibuprofen lysine
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysine (10 mg/kg), followed by 5 mg/kg after 24 h and 48 h
Study: 28262330
Drug: Ibuprofen prophylaxis
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen prophylaxis
Study: 8227846
Drug: Conventional loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional loading dose of amiodarone (600 mg twice a day for 10 days)
Study: 8227846
Drug: High loading
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High loading dose of amiodarone (50 mg/kg per day on days 1-3, 30 mg/kg per day on days 4-5, and 600 mg twice a day on days 6-10)
Study: 12680739
Drug: (S)-ketamine (subanaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-ketamine (subanaesthetic doses)
Study: 10853206
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at subhypnotic dose (1.0 mg/kg/h)
Study: 9358126
Drug: Desirudin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desirudin (15 mg subcutaneously twice daily)
Study: 12100367
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg subcutaneously once daily)
Study: 8415497
Drug: Drug prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug prevention program with 11 lessons (8 in grade 7 and 3 in grade 8), taught by adult teachers and older teens in some schools.
Study: 8415497
Drug: Drug prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug prevention program taught by adults without teen leaders.
Study: 8415497
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment conditions (both groups).
Study: 3463568
Drug: Standard remission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard remission induction treatment
Study: 19000554
Drug: trans-resveratrol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: trans-resveratrol (400 mg) after a standard high fat content meal
Study: 19000554
Drug: trans-resveratrol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: trans-resveratrol (400 mg) after 8 hours of fasting
Study: 12836810
Drug: sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: sibutramine 10 mg once a day
Study: 11144703
Drug: Controlled-release/extended-release metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release/extended-release metoprolol
Study: 12440556
Drug: β-blockers (general)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers (general)
Study: 25534388
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of androgen suppression (AS) followed by radiotherapy with an additional 8 weeks of concurrent AS (16 weeks total)
Study: 21805159
Drug: CPAP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP plus standard treatment
Study: 16702494
Drug: Dexamethasone pulse
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone pulse (DP) therapy
Study: 16702494
Drug: Placebo pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pulse (PP) therapy
Study: 15611396
Drug: Butterbur Ze339
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butterbur Ze339 high dose (1 tablet 3 times daily)
Study: 15611396
Drug: Butterbur Ze339
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butterbur Ze339 low dose (1 tablet twice daily)
Study: 15611396
Drug: Butterbur Ze339
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butterbur Ze339 (both doses)
Study: 11732835
Drug: Modified constraint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint induced therapy (CIT)
Study: 8678251
Drug: 300 IU.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IU.kg‐1 of heparin before bypass
Study: 8678251
Drug: 600 IU.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU.kg‐1 of heparin
Study: 8678251
Drug: 300 IU.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IU.kg‐1 of heparin as bolus followed by a continuous infusion of 10 000 IU.h‐1 until the end of bypass
Study: 8678251
Drug: 600 IU.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU.kg‐1 of heparin plus high dose aprotinin (2 million IU of aprotinin before bypass, 500 000 IU.h‐1 until the end of the operation and 2 million IU added to the bypass pump prime)
Study: 2080791
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human erythropoietin (r‐HuEPO)
Study: 11991886
Drug: Albuterol nebulized
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol nebulized with heliox
Study: 11991886
Drug: Albuterol nebulized
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol nebulized with oxygen (control)
Study: 2949023
Drug: Foscarnet cream
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Foscarnet cream (0.3% in men and 1% in women)
Study: 26662998
Drug: Cardiopoietic stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiopoietic stem cell therapy (600 × 10^6 bone marrow-derived and lineage-directed autologous cardiopoietic stem cells administered via a retention-enhanced intramyocardial injection catheter
Study: 26662998
Drug: Cardiopoietic stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiopoietic stem cell therapy
Study: 20577717
Drug: Buprenorphine (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (4, 8, and 16 mg)
Study: 20577717
Drug: Buprenorphine/naloxone (4/1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (4/1, 8/2, and 16/4 mg)
Study: 20577717
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of buprenorphine
Study: 20577717
Drug: Buprenorphine/naloxone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone combination (low and high doses)
Study: 20577717
Drug: Intramuscular hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hydromorphone (2 and 4 mg)
Study: 1756688
Drug: Ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (400 mg 12 hourly)
Study: 1756688
Drug: Erythromycin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (400 mg every 6 hours)
Study: 7159502
Drug: ethinyl‐estradiol/noretisterone (EE/NET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethinyl‐estradiol/noretisterone (EE/NET) 35 micrograms/0.5 mg
Study: 7159502
Drug: ethinyl‐estradiol/noretisterone (EE/NET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethinyl‐estradiol/noretisterone (EE/NET) 50 micrograms/1 mg
Study: 7159502
Drug: ethinyl‐estradiol/noretisterone (EE/NET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethinyl‐estradiol/noretisterone (EE/NET) 35 micrograms/1 mg
Study: 27745818
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ambrisentan and tadalafil
Study: 27745818
Drug: Monotherapy (ambrisentan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (ambrisentan or tadalafil)
Study: 22498112
Drug: Cetuximab added
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab added to chemotherapy
Study: 17504682
Drug: Isoniazid 300
Normalized name: isoniazid 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 300 mg per day for 6 months (Group I)
Study: 17504682
Drug: Isoniazid 300
Normalized name: isoniazid 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 300 mg per day plus rifampin 600 mg per day for 3 months (Group II)
Study: 9688409
Drug: Cetrorelix 60
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix 60 mg administered i.m. on cycle day 2, followed by a second dose of either 30 or 60 mg based on oestradiol suppression
Study: 870130
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose synthetic human calcitonin (CIBA 47175‐Ba)
Study: 31017382
Drug: Probiotic administration
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic administration (specifically L. reuteri DSM 17938 strain)
Study: 31017382
Drug: Probiotic administration
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic administration during pregnancy and continued after birth
Study: 31017382
Drug: Routine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine administration of probiotics to all infants
Study: 28727796
Drug: Health risk
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health risk assessment (HRA) and monthly counselling sessions with a geriatrician over six months.
Study: 18641106
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg once weekly for 12 months
Study: 12957344
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (0, 21, 35 or 42 mg/day)
Study: 8941106
Drug: 6.25 mg
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.25 mg BID carvedilol (low‐dose group)
Study: 8941106
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg BID carvedilol (medium‐dose group)
Study: 8941106
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg BID carvedilol (high‐dose group)
Study: 1610414
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg b.i.d. for the first month, 240 mg b.i.d. for the second month)
Study: 1610414
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg b.i.d. for the first month, 50 mg b.i.d. for the second month)
Study: 1610414
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of verapamil (240 mg b.i.d.) and captopril (50 mg b.i.d.)
Study: 3158903
Drug: Metronidazole suppositories
Normalized name: metronidazole Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole suppositories (1 g, administered 8-hourly over 20 hours preceding surgery, then 12-hourly if applicable)
Study: 3158903
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole (500 mg infusion at the time of induction)
Study: 3158903
Drug: Both routes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both routes (suppositories and intravenous)
Study: 31738653
Drug: Venetoclax (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (single low initiation dose)
Study: 31738653
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibrutinib and venetoclax
Study: 26866428
Drug: Stopping TNFi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping TNFi treatment
Study: 29745059
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of TNFi treatment
Study: 24707184
Drug: Proactive multifactorial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive multifactorial intervention (PMI) using single-pill amlodipine/atorvastatin
Study: 18728908
Drug: Multifaceted evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted evidence-based medicine intervention (didactic course + recurrent case-method learning sessions)
Study: 12067856
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg testosterone enanthate (TE) weekly
Study: 12067856
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg testosterone enanthate (TE) weekly
Study: 12067856
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg testosterone enanthate (TE) weekly